Clinical experience with therapeutic vaccines designed for patients with hepatit

batibaby

题目：Clinical experience with therapeutic vaccines designed for patients with hepatitis链接：http://lib.bioinfo.pl/pmid:19355957
摘要：Franciscan missionary Giovanni Di Plano Carpini traveled in 1245 to a country named Yeke Tartar, to visit a certain man called Genghis Khan. His journey's report narrated peculiar dietary habits of the locals:"they eat anything, even lice". Little that Carpini knew, he had actually documented the earliest known to us record of oral vaccination against blood-borne infections - an approach that is still used occasionally in the present-day Mongolia for therapy of hepatitis. Currently, efforts aimed at developing therapeutic hepatitis vaccines have switched to more palatable path, but we may still benefit from the insight of medieval Mongols. This review provides an update on development of hepatitis B and C vaccines as related to immunotherapy of hepatitis. Immune therapy is a fast-moving field but the results so far failed to pitch woo. Current trends in research on therapeutic vaccine candidates and liver immunology are discussed. We subscribe to the idea that viral hepatitis is essentially an autoimmune disease generating immune-mediated liver damage. Therapeutic vaccines need to be designed in such a way that self-destructive immunity of the host is targeted not the virus, which is not cytopathic.


哪位在高校能访问国外期刊的，把全文下载下来呗。

StephenW

回复 batibaby 的帖子

This paper is by
                Dendev Batdelger, Yagaanbuyant Dahgwahdorj, Erdene Erdenetsogt, Janchivyn Oyunbileg, Navaansodov Tsend, Bold Bayarmagnai, Vichai Jirathitikal, Aldar S Bourinbaiar   
National Research Center for Infectious Diseases, Ministry of Health, Ulaanbaatar, Mongolia.

Vichai Jirathitikal and Aldar S Bourinbaiar are associated with V5 and Immunitor.

I am cautious.

batibaby

回复 StephenW 的帖子

Yes, maybe the trials of V-5 which worked on with HBV and HCV were precsided by the same men judged from the followed publication. And since V-5 has been released as one product, it should have been got the licence from FDA and have certain effort on HBV and HCB. However, I have not found the public official clinical  data about the V-5 working on HBV or HCB. And the followed three thesises can be found most easily. But, I have no access right to download all of them, so I wish that someone staying in the university can download them in the library to analys the contents.

---------------------------
1> Batdelger D, Dandii D, Jirathitikal V, Bourinbaiar AS. Open label trial of therapeutic hepatitis B vaccine V-5 Immunitor (V5) delivered by oral route. Lett Drug Design Discovery 2007;4:540-44. http://www.ingentaconnect.com/content/ben/lddd/2007/00000004/
2> Batdelger D, Dandii D, Jirathitikal V, Bourinbaiar AS. Open label trial of therapeutic immunization with oral V-5 Immunitor (V5) vaccine in patients with chronic hepatitis C. Vaccine 2008;26:2733-2737.127. http://www.ncbi.nlm.nih.gov/pubmed/18455842
3> Batdelger D, Dandii D, Dahgwahdorj Ya, Erdenetsogt E, Oyunbileg J, Tsend N, Bayarmagnai B, Jirathitikal V, Bourinbaiar AS. Clinical experience with therapeutic vaccines designed for patients with hepatitis. Curr Pharm Design 2009;15:1159-1171. http://www.ncbi.nlm.nih.gov/pubmed/19355957

StephenW

回复 batibaby 的帖子

v5 does not have FDA approval. It is not sold in the USA or Europe or Australia.

batibaby

回复 StephenW 的帖子

怪不得在fda网站上找不到v5的信息，那他在哪卖呀？他被哪个机构批准销售了？